Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE was delisted on the 3rd of May, 2023.
88 hedge funds and large institutions have $125M invested in Jounce Therapeutics, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 38 increasing their positions, 20 reducing their positions, and 26 closing their positions.
107% more call options, than puts
Call options by funds: $448K | Put options by funds: $216K
90% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 20
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
12% less funds holding
Funds holding: 100 → 88 (-12)
38% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 26
43% less capital invested
Capital invested by funds: $221M → $125M (-$95.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$3.58M |
| 2 |
Renaissance Technologies
New York
|
+$1.67M |
| 3 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$1.63M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.61M |
| 5 |
ZIM
Zacks Investment Management
Chicago,
Illinois
|
+$1.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.88M |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$1.76M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.75M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$1.25M |
| 5 |
Two Sigma Investments
New York
|
-$1.08M |
JNCE Hedge Fund Activity: Q1 2020 in Review
88 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q1 2020, worth a combined $125M — down 43% from $221M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of JNCE and 16 opened new positions — a net loss of 10 holders — while 20 trimmed existing stakes and 38 added.
The largest buyer was AQR Capital Management, opening a new position worth an estimated $3.58M. The largest seller was Fidelity Investments, cutting an estimated $3.88M.
- 88 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q1 2020, down from 100 in Q4 2019.
- Funds reported $125M of Jounce Therapeutics, Inc. Common Stock stock for Q1 2020, down 43% quarter-over-quarter.
- 16 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q1 2020 and 26 closed out, a net change of -10 holders.
- The largest Jounce Therapeutics, Inc. Common Stock buyer in Q1 2020 was AQR Capital Management, an estimated $3.58M added.
- The largest Jounce Therapeutics, Inc. Common Stock seller in Q1 2020 was Fidelity Investments, an estimated $3.88M sold.
Based on aggregated 13F filings for Q1 2020.